Clinical Research Directory

Inclusion Criteria: * Patients who voluntarily provide written informed consent prior to any study-specific procedure. * Patients with histologically (or cytologically) confirmed malignant solid tumors, treatment-naïve, with at least one measurable lesion (target lesion). * Age ≥18 and ≤75 years, male or female. * ECOG performance status 0 or 1. * Life expectancy ≥6 months. * Women of childbearing potential must have a negative pregnancy test, and all participants (including male participants) must agree to use effective contraception during the study and for at least 3 months after dosing. Exclusion Criteria: * Pregnant or lactating women, or women planning to become pregnant during the study or within 3 months after dosing (except those who are at least 1 year postmenopausal or surgically sterile \[e.g., bilateral tubal ligation without reversal, bilateral oophorectomy, or hysterectomy\]); or participants planning to donate sperm or oocytes during the study or within 3 months after dosing. * Known or suspected hypersensitivity to the investigational drug or any of its components. * Receipt of another investigational product at enrollment, or within 5 half-lives of that product or 30 days after its last dose, whichever is longer. * Use of any radiotherapeutic agent within 90 days before dosing, or any diagnostic radionuclide within 3 days before dosing. * Significant hepatic or renal impairment: total bilirubin (TBIL) \>1.5×ULN, or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>2.5×ULN, or serum creatinine \>1.5×ULN. * Active infection at screening. * Inability to remain still and supine in the scanner for at least 30 min during SPECT, or claustrophobia or other conditions that preclude cooperation with SPECT. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.